Showing results (81-90 of 88) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Mabs|August 4, 2022
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapySarah C Cowles, Allison Sheen, Luciano Santollani, et al.Molecular Cancer Therapeutics|October 9, 2024
Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor ControlJordan A Stinson, Allison Sheen, Brianna M Lax, et al.Dalton Transactions (Cambridge, England : 2003)|December 22, 2009
On the many roles of NH3 ligands in mono- and multinuclear complexes of platinumPablo J Sanz Miguel, Michael Roitzsch, Lu Yin, et al.Optics Express|February 20, 2026
Dual-pumping supercontinuum generation and temporal reflection in a nonlinear photonic integrated circuitC Khallouf, L Sader, A Bougaud, et al.Nature Communications|March 1, 2024
CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by TregsJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.Biorxiv : the Preprint Server for Biology|February 13, 2023
Tregs constrain CD8+ T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapyJoseph R Palmeri, Brianna M Lax, Joshua M Peters, et al.Proceedings of the National Academy of Sciences of the United States of America|July 24, 2023
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodiesBrianna M Lax, Joseph R Palmeri, Emi A Lutz, et al.Proceedings of the National Academy of Sciences of the United States of America|August 29, 2022
Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapiesEmi A Lutz, Yash Agarwal, Noor Momin, et al.Pageof 9